In October, the Centers for Medicare and Medicaid Services released the 2025 Star Ratings for Medicare Advantage (MA) contracts, along with detailed measure and methodology files supporting these ratings. The numbers show a historic decline in performance. This edition of our Star Rating series discusses the falling Star Ratings for MA and Medicare Advantage Prescription Drug contracts, and explores the factors contributing to the lower ratings and revenue implications. The main sections of this white paper include the following:

• The 2025 Star Rating decline
• Legal challenges
• Closing remarks